NASDAQ:SMMT Summit Therapeutics (SMMT) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free SMMT Stock Alerts $3.69 +0.14 (+3.94%) (As of 10:02 AM ET) Add Compare Share Share Today's Range$3.52▼$3.7450-Day Range$3.28▼$5.0752-Week Range$1.30▼$5.22Volume106,641 shsAverage Volume2.16 million shsMarket Capitalization$2.59 billionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Summit Therapeutics alerts: Email Address Summit Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside125.4% Upside$8.00 Price TargetShort InterestBearish27.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 4 Articles This WeekInsider TradingAcquiring Shares$487,500 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.24) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.33 out of 5 starsMedical Sector693rd out of 908 stocksPharmaceutical Preparations Industry321st out of 423 stocks 3.5 Analyst's Opinion Consensus RatingSummit Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSummit Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted27.60% of the float of Summit Therapeutics has been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Summit Therapeutics has recently increased by 5.00%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSummit Therapeutics does not currently pay a dividend.Dividend GrowthSummit Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SMMT. Previous Next 1.8 News and Social Media Coverage News SentimentSummit Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Summit Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 12 people have searched for SMMT on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Summit Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $487,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders83.70% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.61% of the stock of Summit Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Summit Therapeutics are expected to decrease in the coming year, from ($0.24) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Summit Therapeutics is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Summit Therapeutics is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSummit Therapeutics has a P/B Ratio of 32.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Summit Therapeutics Stock (NASDAQ:SMMT)Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.Read More SMMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SMMT Stock News HeadlinesMarch 29, 2024 | insidertrades.comInsider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Acquires 30,000 Shares of StockApril 24, 2024 | businesswire.comSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024April 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 23, 2024 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Stock Crosses Below Fifty Day Moving Average of $4.14April 11, 2024 | finance.yahoo.comSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsApril 11, 2024 | businesswire.comSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsApril 10, 2024 | businesswire.comSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology ForumApril 9, 2024 | reuters.comIllumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successorApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 9, 2024 | prnewswire.comIllumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development OfficerMarch 29, 2024 | investing.comSummit Therapeutics CEO acquires shares worth over $411kMarch 29, 2024 | fool.comWhy Summit Therapeutics Stock Crushed the Market This WeekMarch 14, 2024 | businesswire.comIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024March 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMTMarch 5, 2024 | businesswire.comSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMTFebruary 27, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Summit Therapeutics Inc. (SMMT) InvestorsFebruary 26, 2024 | businesswire.comSummit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsFebruary 21, 2024 | uk.finance.yahoo.comSummit Therapeutics plc (SMMT)February 21, 2024 | finance.yahoo.comQ4 2023 Summit Therapeutics Inc Earnings CallFebruary 21, 2024 | finance.yahoo.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call TranscriptFebruary 20, 2024 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023February 20, 2024 | finance.yahoo.comSummit Therapeutics Inc (SMMT) Reports Comprehensive 2023 Financial Results and Clinical ...February 20, 2024 | businesswire.comSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023February 17, 2024 | finance.yahoo.comSMMT Mar 2024 4.000 putFebruary 17, 2024 | finance.yahoo.comSMMT Apr 2024 3.000 callFebruary 14, 2024 | businesswire.comSummit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024See More Headlines Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today4/26/2024Next Earnings (Confirmed)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SMMT CUSIPN/A CIK1599298 Webwww.summitplc.com Phone650-460-8308Fax44-12-3544-3999Employees105Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+116.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-614,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.45% Return on Assets-41.17% Debt Debt-to-Equity Ratio1.29 Current Ratio9.30 Quick Ratio9.30 Sales & Book Value Annual Sales$700,000.00 Price / Sales3,698.96 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book33.55Miscellaneous Outstanding Shares701,700,000Free Float114,378,000Market Cap$2.59 billion OptionableOptionable Beta-1.21 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Robert W. Duggan (Age 79)Co-CEO & Executive Chairman Dr. Mahkam Zanganeh D.D.S. (Age 54)M.B.A., Co-CEO, President & Director Comp: $657.81kMr. Ankur Dhingra (Age 47)Chief Financial Officer Comp: $530kMr. Manmeet Singh Soni (Age 46)COO & Director Comp: $591.5kProf. Dame Kay Davies DBE (Age 73)FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor Ms. Abby Guzman MurphyHead of Human ResourcesMs. Divya Chari (Age 56)Head of Global Clinical Operations Mr. Dave GancarzChief Business & Strategy Officer?Mr. Will BlackHead of Information Technology?Dr. Betty Y. Chang Ph.D.Head of Research, Oncology & Inflammation?More ExecutivesKey CompetitorsJanux TherapeuticsNASDAQ:JANXIndiviorNASDAQ:INDVEvotecNASDAQ:EVOMorphoSysNASDAQ:MORACADIA PharmaceuticalsNASDAQ:ACADView All CompetitorsInsiders & InstitutionsWealth Management Partners LLCBought 29,000 shares on 4/12/2024Ownership: 0.006%Ankur DhingraBought 100,000 shares on 3/26/2024Total: $375,000.00 ($3.75/share)Mahkam ZanganehBought 30,000 shares on 3/26/2024Total: $112,500.00 ($3.75/share)Sectoral Asset Management Inc.Bought 10,000 shares on 2/14/2024Ownership: 0.004%Aristides Capital LLCBought 80,601 shares on 2/13/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions SMMT Stock Analysis - Frequently Asked Questions Should I buy or sell Summit Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SMMT shares. View SMMT analyst ratings or view top-rated stocks. What is Summit Therapeutics' stock price target for 2024? 1 Wall Street analysts have issued 1 year price objectives for Summit Therapeutics' stock. Their SMMT share price targets range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 125.4% from the stock's current price. View analysts price targets for SMMT or view top-rated stocks among Wall Street analysts. How have SMMT shares performed in 2024? Summit Therapeutics' stock was trading at $2.61 at the beginning of the year. Since then, SMMT stock has increased by 36.0% and is now trading at $3.55. View the best growth stocks for 2024 here. Are investors shorting Summit Therapeutics? Summit Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 21,810,000 shares, an increase of 28.6% from the March 15th total of 16,960,000 shares. Based on an average daily volume of 2,340,000 shares, the short-interest ratio is currently 9.3 days. Approximately 26.3% of the company's stock are sold short. View Summit Therapeutics' Short Interest. When is Summit Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our SMMT earnings forecast. How can I listen to Summit Therapeutics' earnings call? Summit Therapeutics will be holding an earnings conference call on Wednesday, May 1st at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics Inc. (NASDAQ:SMMT) issued its earnings results on Tuesday, February, 20th. The company reported ($0.05) earnings per share for the quarter. The company earned $0.20 million during the quarter. What ETFs hold Summit Therapeutics' stock? ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP). When did Summit Therapeutics IPO? Summit Therapeutics (SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager. Who are Summit Therapeutics' major shareholders? Summit Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wealth Management Partners LLC (0.01%). Insiders that own company stock include Ankur Dhingra, Mahkam Zanganeh, Maky Zanganeh, Manmeet Singh Soni and Robert W Duggan. View institutional ownership trends. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SMMT) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.